Clinical references

The following two links will take you to the respective releases of Forest Laboratories, Inc.:

• Data on Citalopram® studies in children and adolescents.
• Data on Lexapro® study in children and adolescents.

The following posters and abstracts presenting the results of the clinical trials are available as Adobe PDF files. You can download the free Adobe Acrobat Reader plug-in at: www.adobe.com.

You will find the posters and abstracts under the respective congress and under each congress you will find the information listed chronologically.

• ACNP - The American College of Neuro-Psychopharmacology
• ADAA - Anxiety Disorders Association of America
• APSS - Associated Professional Sleep Societies 
• 7th International Conference AD/PD
• APA - American Psychiatric Association
• ECNP - European College of Neuro-Psychopharmacology
• IADC - International Anxiety Disorders Conference
• International Conference on Alzheimer's Disease and Related Disorders
• SCNP - Scandinavian College of Neuro-Psychopharmacology

 

Posters presented at the 42nd congress of the American College of Neuro-Psychopharmacology in Puerto Rico, December 2003.

Comparison of escitalopram with sertraline (PDF, 184KB)
Comparison of escitalopram with paroxetine in GAD (PDF, 2,052KB)
Switching patients from citalopram to escitalopram (PDF, 140KB)
Effect of escitalopram in pain (PDF, 89KB)

 

Posters presented at the 45th congress of the American College of Neuro-Psychopharmacology in USA, December 2006.

Escitalopram - comparison with duloxetine (PDF, 289 kb)

Bifeprunox - 6-month maintenance - 10214 study (PDF, 102 kb)
Bifeprunox - 6 week acute, results of dose finding study - 2010 study (PDF, 82 kb)
Bifeprunox - 6 week acute, 3001 study (PDF, 82 kb)
Bifeprunox - 6 week acute, 3003 study (PDF, 77 kb)
Bifeprunox - metabolic profile (PDF, 77 kb)

 

Poster presented at the 23rd National Conference of Anxiety Disorders Association of America in Toronto, Canada, March 2003.

Escitalopram prevents relapse in patients suffering from SAD (PDF, 128KB)

 

The enclosed results from three clinical studies on Cipralex® for the treatment of different anxiety disorders were presented at the annual meeting of the Anxiety Disorders Association of America (ADAA) in Austin, Texas, USA, March 2002.

Escitalopram in the treatment of Generalized Anxiety Disorder (PDF, 5KB)
Escitalopram in the treatment of panic disorder (PDF, 6KB)
Escitalopram is efficacious and well tolerated in the treatment of Social Anxiety Disorder (PDF, 6KB)

 

The enclosed two abstracts for Ebixa® (memantine) were presented at the 7th International Conference AD/PD in Sorrento, Italy.

Efficacy and tolerability of memantine - a naturalistic study (PDF, 52 KB)
Switching from donepezil to memantine (PDF, 116 KB)

 

These posters were presented at the American Psycgiatric Association meeting in Toronto, Canada in May 2006.

Gaboxadol in primary insomnia (Phase II) (PDF, 59 Kb)
Gaboxadol in transient insomnia (Phase II) (PDF, 92 Kb)

 

These posters were presented at the American Psychiatric Association meeting in Philadelphia, USA, May 2002.

Escitalopram in the treatment of panic disorder (PDF,  36KB)
Escitalopram is a well tolerated SSRI (PDF, 36KB)
Escitalopram is efficacious and well tolerated in the treatment of SAD (PDF, 48KB)
Escitalopram, a new treatment for depression and anxiety (PDF, 56KB)

 

The results of several clinical studies including two pooled analyses of three, phase III placebo-controlled studies were published at the American Psychiatric Association meeting on May 9, 2001, in New Orleans, USA.

Fixed dose study of escitalopram in the treatment of depression (PDF, 23KB)
Comparison of efficacy in placebo-controlled trials of escitalopram and citalopram (PDF, 23KB)
Effects of escitalopram on anxiety symptoms in depression (PDF, 21KB)
Escitalopram 10 mg/day: Effective Antidepressant in Primary Care (PDF, 37KB)

 

The results were published at the Associated Professional Sleep Society meeting 17-22 June 2006, in Salt Lake City, Utah, USA.

Spectral Profiles During NREM Sleep for Gaboxadol and Zolpidem in Treatment of Patients with Primary Insomnia (PDF, 540KB)
Pharmacological Characterization of Agonists at d-containing GABAA Receptors: Functional Selectivity for Extrasynaptic Receptors is Dependent on Absence of g (PDF, 327KB) 

 

Poster presented at the 17th congress of the European College of Neuro-Psychopharmacology in Stockholm, Sweden, October 2004.

Escitalopram and paroxetine in GAD (PDF, 92KB)

 

Poster presented at the 16th congress of the European College of Neuro-Psychopharmacology in Prague, Czech Republic, September 2003.

Comparison of escitalopram with venlafaxine XR (PDF, 180KB)

 

These posters were presented at the European College of Neuropsychopharmacology congress in Barcelona, Spain, October 2002.

Escitalopram offers early separation from placebo (PDF, 57KB)
Improvement during long-term Escitalopram-treatment (PDF, 71KB)

 

Posters presented on the International Anxiety Disorders Conference in Cape Town, South Africa, 24-26 February 2006

Escitalopram better than paroxetine in severe depression (PDF, 82 Kb)

 

Following abstracts were presented at the 8th International Conference on Alzheimer's Disease and Related Disorders in Stockholm, Sweden, July 2002.

Abstracts (PDF, 3.1MB)

 

Poster presented at the 44th meeting of the Scandinavian College of Neuro-Psychopharmacology in Juan-Le-Pins, France, April 2003.

Escitalopram and paroxetine for the treatment of SAD (PDF, 95KB)
Escitalopram and Venlafaxine XR in the treatment of depression (PDF, 89KB)